Modulators of hERAP2 discovered by High-Throughput Screening - Archive ouverte HAL Access content directly
Journal Articles European Journal of Medicinal Chemistry Year : 2020

Modulators of hERAP2 discovered by High-Throughput Screening

Peter van Endert


Endoplasmic reticulum aminopeptidase 2, ERAP2, is an emerging pharmacological target in cancer immunotherapy and control of autoinflammatory diseases, as it is involved in antigen processing. It has been linked to the risk of development of spondyloarthritis, and it associates with the immune infiltration of tumours and strongly predicts the overall survival for patients receiving check-point inhibitor therapy. While some selective inhibitors of its homolog ERAP1 are available, no selective modulator of ERAP2 has been disclosed so far. In order to identify such compounds, we screened an in-house focused library of 1920 compounds designed to target metalloenzymes. Structure-Activity Relationships and docking around two hits led to the discovery of selective inhibitors of ERAP2. Amid those, some bind to yet untapped amino-acids in the S1 pocket. Importantly, we disclose also the first activator of small substrates hydrolysis by ERAP2. Inhibitors and activators identified in this study could serve as useful starting points for optimization.
Fichier principal
Vignette du fichier
S0223523420310254.pdf (1.83 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03059990 , version 1 (02-01-2023)


Attribution - NonCommercial



Laura Medve, Ronan Gealageas, Vy Lam Bao, Valentin Guillaume, Omar Castillo-Aguilera, et al.. Modulators of hERAP2 discovered by High-Throughput Screening. European Journal of Medicinal Chemistry, 2020, 211, pp.113053. ⟨10.1016/j.ejmech.2020.113053⟩. ⟨hal-03059990⟩
105 View
20 Download



Gmail Facebook X LinkedIn More